Innate Pharma (IPHA) Net Cash Flow (2019 - 2025)

Innate Pharma has reported Net Cash Flow for 7 years, with the latest figure at -$61.4 million in Q4 2025.

• For the quarter ending Q4 2025, Net Cash Flow fell 345.34% year-over-year to -$61.4 million; the trailing twelve-month figure through Dec 2025 stood at -$75.2 million (down 15.61% YoY), and the FY2025 full-year result was -$45.9 million, down 1058.61% from the prior year.
• Net Cash Flow for Q4 2025 stood at -$61.4 million, down from -$13.8 million in the prior quarter.
• The five-year high for Net Cash Flow was -$1.4 million in Q2 2022, with the low at -$67.9 million in Q4 2021.
• Historically, Net Cash Flow has averaged -$32.1 million across 5 years, with a median of -$29.3 million in 2022.
• Annual changes were most pronounced in 2022 — Net Cash Flow soared 96.32% — and 2023, when it plunged 875.83%.
• Innate Pharma's Net Cash Flow stood at -$67.9 million in 2021, then soared by 68.48% to -$21.4 million in 2022, then tumbled by 73.52% to -$37.1 million in 2023, then soared by 62.88% to -$13.8 million in 2024, then plunged by 345.34% to -$61.4 million in 2025.
• The last three Net Cash Flow figures came in at -$61.4 million (Q4 2025), -$13.8 million (Q4 2024), and -$37.1 million (Q4 2023), per Business Quant data.